Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

7.360 +0.900 (+13.93%)
Streaming Delayed Price Updated: 2:09 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Agenus Inc

< Previous 1 2 3 Next >
Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO
From Agenus Inc.
Via Business Wire
Agenus Announces Virtual Annual Shareholders Meeting
From Agenus
Via Business Wire
Agenus to Participate in Jefferies Healthcare Conference
From Agenus
Via Business Wire
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
From Agenus Inc.
Via Business Wire
Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI
From Agenus
Via Business Wire
Agenus (NASDAQ: AGEN) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting
From Agenus
Via Business Wire
Agenus to Provide Corporate Update and First Quarter 2023 Financial Report
From Agenus
Via Business Wire
Agenus to Participate in May Investor Conferences
From Agenus
Via Business Wire
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
From Agenus Inc.
Via Business Wire
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
From Agenus Inc.
Via Business Wire
Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer
From Agenus Inc.
Via Business Wire
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
From Agenus Inc.
Via GlobeNewswire
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
Conference Call Cancelled 
From Agenus Inc.
Via GlobeNewswire
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET 
From Agenus Inc.
Via GlobeNewswire
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
Conference Call on Tuesday, March 14, 2023 at 8:30 a.m. ET 
From Agenus Inc.
Via GlobeNewswire
Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
From Agenus Inc.
Via GlobeNewswire
Agenus to Participate in February Investor Conferences
From Agenus Inc.
Via GlobeNewswire
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
From Agenus Inc.
Via GlobeNewswire
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
From Agenus Inc.
Via GlobeNewswire
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
From Agenus Inc.
Via GlobeNewswire
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma
From Agenus Inc.
Via GlobeNewswire
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
From Agenus Inc.
Via GlobeNewswire
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
From Agenus Inc.
Via GlobeNewswire
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
From Agenus Inc.
Via GlobeNewswire
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
From Agenus Inc.
Via GlobeNewswire
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
From Agenus Inc.
Via GlobeNewswire
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
From Agenus Inc.
Via GlobeNewswire
Agenus to Host “The Road Taken” R&D Event on November 12, 2022
From Agenus Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.